Alan J. Korman
89Patents
22h-index
113Co-inventors
91Inventor score
Filing activity: Jul 29, 1999 → Feb 27, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8008449B2 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics | Emerging Cross-Sectional Technologies | 812 | Active |
| US7943743B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 541 | Active |
| US6984720B1 | Human CTLA-4 antibodies | Emerging Cross-Sectional Technologies | 252 | Expired |
| US8779105B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 204 | Active |
| US8383796B2 | Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 148 | Active |
| US9084776B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 134 | Active |
| US7605238B2 | Human CTLA-4 antibodies and their uses | Emerging Cross-Sectional Technologies | 122 | Expired |
| US9492540B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 116 | Active |
| US9358289B2 | Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies | Emerging Cross-Sectional Technologies | 112 | Active |
| US9387247B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 98 | Active |
| US9492539B2 | Monoclonal antibodies to Programmed Death 1 (PD-1) | Emerging Cross-Sectional Technologies | 96 | Active |
| US6171795A | Nucleic acid ligands to CD40ligand | Human Necessities | 93 | Expired |
| US9102725B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 90 | Active |
| US9273135B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 77 | Active |
| US8017114B2 | Human CTLA-4 antibodies and their uses | Emerging Cross-Sectional Technologies | 55 | Active |
| US8287856B2 | PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | Human Necessities | 48 | Active |
| US9580507B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 47 | Active |
| US7452535B2 | Methods of treatment using CTLA-4 antibodies | Human Necessities | 46 | Expired |
| US9580505B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 31 | Active |
| US8580247B2 | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | Human Necessities | 31 | Active |
| US9228016B2 | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | Physics | 31 | Active |
| US8263073B2 | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof | Chemistry; Metallurgy | 26 | Active |
| US10441655B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 21 | Active |
| US10344089B2 | Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof | Chemistry; Metallurgy | 20 | Active |
| US9605080B2 | Antibodies against CD73 | Physics | 19 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.